Biogen reports two-year Phase 2 CELIA findings for diranersen, showing 38% slower clinical decline on CDR-SB at Week 96 in early Alzheimer’s disease.
Written By: Pavani Polepaka, PharmD
Reviewed By: Pharmacally Editorial Team
Biogen has reported two-year clinical and biomarker findings from the ongoing Phase 2 CELIA trial (NCT05399888) evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in adults with early Alzheimer’s disease. Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, the results indicate sustained slowing of clinical decline through Week 96. Among the evaluated regimens, the 60 mg intrathecal dose administered twice yearly generated the largest treatment effects, showing greater relative slowing across five of six clinical measures compared with the 18-month assessment.
Clinical Findings at Week 96
In participants receiving diranersen 60 mg every 24 weeks, clinical decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) slowed by 38% at Week 96 compared with participants originally randomized to placebo, up from 26% at Week 76. This corresponded to a 1.09-point treatment difference on CDR-SB, exceeding the one-point threshold generally regarded by clinicians as clinically meaningful in early Alzheimer’s disease.
The Week 96 comparison included 60 participants treated with the 60 mg twice-yearly regimen and 115 participants originally assigned to placebo. Across secondary and exploratory cognitive, functional, and composite endpoints, treatment-effect estimates widened between Week 76 and Week 96 on four additional scales, while declining on the Mini-Mental State Examination (MMSE).
Clinical Endpoint | Week 76 treatment effect (%) | Week 96 treatment effect (%) |
Clinical Dementia Rating–Sum of Boxes (CDR-SB) | 26% | 38% |
Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog13) | 42% | 54% |
ADCS–Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) | 0% | 30% |
Alzheimer’s Disease Composite Score (ADCOMS) | 23% | 38% |
Modified Integrated Alzheimer’s Disease Rating Scale (iADRS) | 30% | 46% |
Mini-Mental State Examination (MMSE) | 50% | 38% |
Primary Endpoint Miss and Open-Label Interpretation
Despite the numerical improvements observed at two years, the CELIA study did not meet its primary endpoint of demonstrating a statistically significant dose-response relationship in CDR-SB change from baseline at Week 76. The trial was structured to determine whether higher doses or more frequent intrathecal administration would yield greater clinical benefit. Prespecified analyses instead indicated slowing of decline across active dosing arms without a linear dose gradient, with the 60 mg twice-yearly schedule demonstrating the most consistent clinical signal.
Crucially, the Week 96 data derive from the study’s open-label extension (OLE) rather than the double-blind, placebo-controlled phase. The two-year treatment estimates compare participants who remained on their assigned diranersen regimen against a delayed-start comparator group comprising participants originally assigned to placebo who transitioned into the extension. By Week 96, individuals in the comparator cohort had received either zero or one dose of diranersen, serving as a placebo-equivalent reference. Because open-label analyses lack concurrent randomized masking and are subject to potential selection and expectation biases, these two-year estimates require confirmation in controlled Phase 3 trials.
Mechanism of Action
Pathological accumulation of hyperphosphorylated tau protein correlates closely with neurodegeneration and cognitive deterioration in Alzheimer’s disease. Diranersen is designed to bind selectively to microtubule-associated protein tau (MAPT) messenger RNA, promoting its degradation and reducing the translation of all tau protein isoforms. Unlike monoclonal antibodies that target extracellular tau species, diranersen acts upstream at the RNA level to lower both intracellular and extracellular tau production.
CELIA Trial Design and Biomarker Readouts
CELIA is a global, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 trial that enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia who had not previously received anti-amyloid therapies. During the 76-week controlled treatment period, participants were randomized to placebo or one of three intrathecal diranersen regimens: 60 mg every 24 weeks, 115 mg every 24 weeks, or 115 mg every 12 weeks.
Biomarker findings from the 18-month readout at the Alzheimer’s Association International Conference (AAIC) 2026 demonstrated mean reductions of 50–65% in cerebrospinal fluid (CSF) total tau across active treatment arms, accompanied by broad reductions in brain tau pathology on positron emission tomography (PET). The CTAD 2026 update further underscored reductions in CSF phosphorylated tau 181 (p-tau181) and plasma phosphorylated tau 217 (p-tau217), reinforcing target engagement and downstream biological activity.
Safety Profile and Regulatory Status
Diranersen maintained a favorable tolerability profile through two years of follow-up, with no new safety signals identified in the extension phase. During the initial 76-week placebo-controlled period, the majority of adverse events were mild to moderate in severity, non-serious, and did not lead to treatment discontinuation or study withdrawal. Ongoing follow-up in the extension continues to evaluate long-term safety and the durability of clinical and biomarker responses.
The U.S. Food and Drug Administration granted diranersen Fast Track designation for Alzheimer’s disease in 2025. Diranersen remains an investigational candidate not yet approved by any regulatory agency, and pivotal Phase 3 evaluation will be required to confirm its efficacy and inform optimal dose selection.
Reference
Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease, Biogen, November 17 2026
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants with Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA), ClinicalTrials.gov ID NCT05399888
About the Writer
Pavani Polepaka, Pharm.D., (Linkedin) is a clinically trained pharmacy professional with hands-on exposure to hospital settings and experience in patient case documentation, medical record review, adverse drug reaction (ADR) reporting, pharmacovigilance, literature review and patient counselling. She possesses a strong foundation in pharmacotherapy, drug safety, clinical research and evidence-based healthcare practices, with an interest in translating clinical evidence into scientifically accurate medical content. She demonstrates research and analytical skills through academic activities and medical literature evaluation.
